Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC
Top Cited Papers
Open Access
- 25 January 2017
- journal article
- research article
- Published by Elsevier BV in Journal of Hepatology
- Vol. 66 (6), 1166-1172
- https://doi.org/10.1016/j.jhep.2017.01.012
Abstract
No abstract availableThis publication has 37 references indexed in Scilit:
- Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolizationJournal of Hepatology, 2013
- Radiographic Response to Locoregional Therapy in Hepatocellular Carcinoma Predicts Patient Survival TimesGastroenterology, 2011
- Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinomaCancer, 2011
- Modified RECIST (mRECIST) Assessment for Hepatocellular CarcinomaSeminars in Liver Disease, 2010
- Sorafenib in Advanced Hepatocellular CarcinomaThe New England Journal of Medicine, 2008
- Reflections on Medical Oncology: 25 Years of Clinical Trials—Where Have We Come and Where Are We Going?Journal of Clinical Oncology, 2008
- Surrogate End Points for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis From 39 Randomized Controlled Trials of First-Line ChemotherapyJournal of Clinical Oncology, 2007
- Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinomaHepatology, 2004
- Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialThe Lancet, 2002
- Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL ConferenceJournal of Hepatology, 2001